News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
News
ASX Lunch Wrap: Xero lifts ASX higher; Selfwealth skyrockets after attracting another suitor
Health & Biotech
Health Check: Experts deliver their verdict on the Healius imaging deal and it’s ‘yeah nah’
Health & Biotech
Alive and Kicking: Respiri promises breath of life to bottom line after inking US distribution deal
News
Market Highlights: ASX to test new record in a high-stakes week; and 5 small caps to watch
News
ASX Rebalance: Copper in, lithium out as hot biotechs climb ranks
Health & Biotech
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
Health & Biotech
ASX Health Stocks: Inoviq’s tech boosts early detection of Parkinson’s disease
News
Market Highlights: Wall Street rallies hard after inflation data; Starbucks steals Chipotle’s CEO
Health & Biotech
ASX Health Stocks: Immutep gets positive FDA feedback for lung cancer therapy
News
Market Highlights: CrowdStrike plunges 11pc after global outage, as Biden pulls out of race
Health & Biotech
ASX Health Stocks: Immutep gets crucial therapy trial clearance; Alcidion wins $4m deal
News
Top 10 at 11: A positive drug trial and investor webinars are making news today
Health & Biotech
ScoPo’s Powerplays: ASX health stocks end the week ahead despite freaky inflation data
News
Closing Bell: Abominable inflation has ASX in full retreat
Health & Biotech
ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial
News
Market Highlights: Amazon hits US$2T cap for first time, and property market to remain strong next year
News
